Scaling-up experiments of smouldering combustion as a remediation technology for contaminated soil

Self-sustaining Treatment for Active Remediation (STAR) is a novel, patent-pending process that uses smouldering combustion as a remediation technology for land contaminated with hazardous organic liquids. Compounds such as chlorinated solvents, coal tar and petroleum products, called Non-Aqueous Phase Liquids (NAPLs) for their low miscibility with water, have a long history of use in the industrialised world and are among the most ubiquitous of contaminants worldwide. These contaminants are toxic and many are suspected or known carcinogens. Existing remediation technologies are expensive and ineffective at reducing NAPL source zones sufficiently to restore affected water resources to appropriate quality levels. STAR introduces a self-sustaining smouldering reaction within the NAPL pool in the subsurface and allows that reaction to provide all of the post-ignition energy required by the reaction to completely remediate the NAPL source zone in the soil. Results from laboratory and field experiments have been very promising. Laboratory experiments have demonstrated STAR across a wide range of NAPL fuels and focused on coal tar to identify key parameters for successful remediation. Modelling has suggested that STAR efficiency will improve with scale as effects such as heat losses from boundaries become less significant. Observations from field experiments support the modelling theory - significantly lower relative air flow in a smouldering field experiment (330L) led to faster smouldering front propagation than observed in laboratory experiments (1L and 3L). Preliminary emissions monitoring by Fourier Transform Infrared (FTIR) spectroscopy has suggested that STAR emissions might be low enough to meet regulatory requirements, but further study is necessary. As emissions are expected to vary with each contaminant, activated carbon filters are being developed and tested in case emissions filtration is necessary. Experiments at all scales have demonstrated that STAR is controllable and self-terminating. Pilot-scale (2500L) field trials are underway to demonstrate STAR on excavated contaminated soil. The materials that will be studied in these trials are manufactured coal tar in coarse sand (which is the same material as used in the laboratory and field experiments) as well as two soils obtained from coal tar contaminated sites. This poster focuses on the scale-up to these field trials, including small scale characterisation, large scale performance, emissions monitoring and post-treatment soil analysis

Experimental studies of self-sustaining thermal aquifer remediation (STAR) for non-aqueous phase liquid (NAPL) sources

Self-sustaining Thermal Aquifer Remediation (STAR) is a novel technology that employs smouldering combustion for the remediation of subsurface contamination by non-aqueous phase liquids (NAPLs). Smouldering is a form of combustion that is slower and less energetic than flaming combustion. Familiar examples of smouldering involve solid fuels that are destroyed by the reaction (e.g., a smouldering cigarette or peat smouldering after a wildfire). In STAR, the NAPL serves as the fuel within an inert, porous soil medium. Results from experiments across a range of scales are very promising. Detailed characterisation has focused on coal tar, a common denser-than-water NAPL (DNAPL) contaminant. Complete remediation is demonstrated across this range of scales. Visual observations are supported bychemical extraction results. Further experiments suggest that STAR can be self-sustaining, meaning that once ignited the process can supply its own energy to propagate. Costly energy input is reduced significantly. Comparison of large scale to small scale laboratory experiments, a volume increase by a factor of 100, suggests that STAR process efficiency increases with scale. This increase in efficiency results from reduced heat losses at larger scales while maximum the temperature achieved by STAR is unaffected. The research also demonstrates the controllability of STAR, where the termination of airflow to the reaction terminates the STAR process. The scale-up process provides important guidance to the development of full scale STAR for ex situ remediation of NAPL-contaminated soil

NEUROD1 mutation in an Italian patient with maturity onset diabetes of the young 6: a case report

Background: Maturity Onset Diabetes of the Young (MODY) is a monogenic, autosomal, dominant disease that results in beta-cells dysfunction with consequent hyperglycaemia. It represents a rare form of diabetes (1–2% of all the cases). Sulphonylureas (SUs) represent the first-line treatment for this form of diabetes mellitus. NEUROD1 is expressed by the nervous and the pancreatic tissues, and it is necessary for the proper development of beta cells. A neurogenic differentiation factor 1 (NEUROD1) gene mutation causes beta-cells dysfunction, inadequate insulin secretion, and hyperglycaemia (MODY 6). Case presentation: We have documented a new missense mutation (p.Met114Leu c.340A > C) of the NEUROD1 gene, pathogenetic for diabetes mellitus, in a 48 years-old man affected by diabetes since the age of 25 and treated with insulin basal-bolus therapy. Unfortunately, an attempt to replace rapid insulin with dapagliflozin has failed. However, after the genetic diagnosis of MODY6 and treatment with SUs, he was otherwise able to suspend rapid insulin and close glucose monitoring. Interestingly, our patient had an early onset dilated cardiomyopathy, though no data about cardiac diseases in patients with MODY 6 are available. Conclusions: Diagnostic criteria for MODY can overlap with other kinds of diabetes and most cases of genetic diabetes are still misdiagnosed as diabetes type 1 or 2. We encourage to suspect this disease in patients with a strong family history of diabetes, normal BMI, early-onset, and no autoimmunity. The appropriate therapy simplifies disease management and improves the quality of the patient’s life

Small-scale forward smouldering experiments for remediation of coal tar in inert media

This paper presents a series of experiments conducted to assess the potential of smouldering combustion as a novel technology for remediation of contaminated land by water-immiscible organic compounds. The results from a detailed study of the conditions under which a smouldering reaction propagates in sand embedded with coal tar are presented. The objective of the study is to provide further understanding of the governing mechanisms of smouldering combustion of liquids in porous media. A small-scale apparatus consisting of a 100 mm in diameter quartz cylinder arranged in an upward configuration was used for the experiments. Thermocouple measurements and visible digital imaging served to track and characterize the ignition and propagation of the smouldering reaction. These two diagnostics are combined here to provide valuable information on the development of the reaction front. Post-treatment analyses of the sand were used to assess the amount of coal tar remaining in the soil. Experiments explored a range of inlet airflows and fuel concentrations. The smouldering ignition of coal tar was achieved for all the conditions presented here and self-sustained propagation was established after the igniter was turned off. It was found that the combustion is oxygen limited and peak temperatures in the range 800-1080 °C were observed. The peak temperature increased with the airflow at the lower range of flows but decreased with airflow at the higher range of flows. Higher airflows were found to produce faster propagation. Higher fuel concentrations were found to produce higher peak temperatures and slower propagation. The measured mass removal of coal tar was above 99% for sand obtained from the core and 98% for sand in the periphery of the apparatus

Bone mineral density in patients on home parenteral nutrition: a follow-up study.

Home artificial nutrition

Reconnection surgery in adult post-operative short bowel syndrome < 100 cm: is colonic continuity sufficient to achieve enteral autonomy without autologous gastrointestinal reconstruction? Report from a single center and systematic review of literature

A systematic bibliographic research concerning patients operated on for SBS was performed: inclusion criteria were adult age, reconnection surgery and SBS &lt; 100 cm. Autologous gastrointestinal reconstruction represented an exclusion criteria. The outcomes of interest were the rate of total parenteral nutrition (TPN) independence and the length of follow-up (minimum 1 year) after surgery. We reviewed our experience from 2003 to 2013 with minimum 1-year follow-up, dealing with reconnection surgery in 13 adults affected by &lt; 100 cm SBS after massive small bowel resection: autologous gastrointestinal reconstruction was not feasible. Three (out of 5168 screened papers) non randomized controlled trials with 116 adult patients were analysed showing weaning from TPN (40%, 50% and 90% respectively) after reconnection surgery without autologous gastrointestinal reconstruction. Among our 13 adults, mean age was 54.1 years (53.8 % ASA III): 69.2 % had a high stomal output (&gt; 500 cc/day) and TPN dependence was 100%. We performed a jejuno-colonic anastomosis (SBS type II) in 53.8%, in 46.1% of cases without ileo-cecal valve, leaving a mean residual small bowel length of 75.7 cm. In-hospital mortality was 0%. After a minimum period of 1 year of intestinal rehabilitation, all our patients (100%) went back to oral intake and 69.2% were off TPN (9 patients). No one was listed for transplantation. A residual small bowel length of minimum 75 cm, even if reconnected to part of the colon, seems able to produce a TPN independence without autologous gastrointestinal reconstruction after a minimum period of 1 year of intestinal rehabilitation

Fish oil-based emulsion for the treatment of parenteral nutrition associated liver disease in an adult patient

Background &amp; aims: Reversal of parenteral nutrition associated liver disease with fish oil emulsion (FO) has been reported in infants. We report a similar case in an adult patient. Methods: A 58 year-old female on home parenteral nutrition for a short bowel syndrome due to Crohn's disease, showed a progressive worsening of liver steatosis, and a persistent increase of the plasma liver function tests (LFTs). LFTs, serum alpha-tochopherol, red blood cell membrane fatty acids and liver histology were evaluated before and after an 8 month treatment with FO. Results: The patient's LFT's improved. There was an increase of the n-3 and a decrease of the n-6 series of fatty acids in erythrocyte membrane. There was an approximate 30% increase in vitamin E status. Before FO, liver histology showed a non-alcoholic steatohepatitis with grade 2 steatosis and inflammation and stage 3 fibrosis. After the treatment, steatosis and inflammation were grade 1, whereas fibrosis remained at stage 3. Conclusions: Infusion of FO was associated with consistent changes of cell membrane fatty acid structure and with mild improvement of vitamin E status. A potential role of FO in decreasing liver steatosis and inflammation with no change of liver fibrosis might be suggested. © 2010 European Society for Clinical Nutrition and Metabolism

Home parenteral nutrition with an omega-3-fatty-acid-enriched MCT/LCT lipid emulsion in patients with chronic intestinal failure (the HOME study):study protocol for a randomized, controlled, multicenter, international clinical trial

BACKGROUND: Home parenteral nutrition (HPN) is a life-preserving therapy for patients with chronic intestinal failure (CIF) indicated for patients who cannot achieve their nutritional requirements by enteral intake. Intravenously administered lipid emulsions (ILEs) are an essential component of HPN, providing energy and essential fatty acids, but can become a risk factor for intestinal-failure-associated liver disease (IFALD). In HPN patients, major effort is taken in the prevention of IFALD. Novel ILEs containing a proportion of omega-3 polyunsaturated fatty acids (n-3 PUFA) could be of benefit, but the data on the use of n-3 PUFA in HPN patients are still limited. METHODS/DESIGN: The HOME study is a prospective, randomized, controlled, double-blind, multicenter, international clinical trial conducted in European hospitals that treat HPN patients. A total of 160 patients (80 per group) will be randomly assigned to receive the n-3 PUFA-enriched medium/long-chain triglyceride (MCT/LCT) ILE (Lipidem/Lipoplus® 200 mg/ml, B. Braun Melsungen AG) or the MCT/LCT ILE (Lipofundin® MCT/LCT/Medialipide® 20%, B. Braun Melsungen AG) for a projected period of 8 weeks. The primary endpoint is the combined change of liver function parameters (total bilirubin, aspartate transaminase and alanine transaminase) from baseline to final visit. Secondary objectives are the further evaluation of the safety and tolerability as well as the efficacy of the ILEs. DISCUSSION: Currently, there are only very few randomized controlled trials (RCTs) investigating the use of ILEs in HPN, and there are very few data at all on the use of n-3 PUFAs. The working hypothesis is that n-3 PUFA-enriched ILE is safe and well-tolerated especially with regard to liver function in patients requiring HPN. The expected outcome is to provide reliable data to support this thesis thanks to a considerable number of CIF patients, consequently to broaden the present evidence on the use of ILEs in HPN. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03282955. Registered on 14 September 2017